Annovis Bio CEO to Present at H.C. Wainwright Global Investment Conference

Annovis Bio Inc. (NYSE: ANVS) announced that CEO Maria Maccecchini, Ph.D., will present at the H.C. Wainwright 27th Annual Global Investment Conference scheduled for September 8-10, 2025. The conference will take place at the Lotte New York Palace Hotel in New York City, providing a platform for the company to showcase its progress and developments to the investment community.

The presentation represents a significant opportunity for Annovis Bio to communicate its strategic vision and recent advancements in neurodegenerative disease treatment. For investors and stakeholders, such conferences serve as critical venues for gaining insights into a company's pipeline, clinical progress, and future direction. The participation indicates Annovis Bio's ongoing commitment to transparency and engagement with the financial community.

Annovis Bio focuses on developing innovative therapies for neurodegeneration in diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD). The company's dedication to improving patient outcomes and quality of life through novel treatments positions it within a growing sector of the biotechnology industry. Neurodegenerative diseases affect millions worldwide, creating substantial market opportunities for effective therapies.

The conference presentation may provide updates on the company's clinical trials, research developments, or regulatory progress. Such updates are crucial for investors assessing the company's potential and for patients and healthcare providers awaiting new treatment options. The neurodegenerative disease treatment market represents a multi-billion dollar industry with significant unmet medical needs.

For those seeking additional information about Annovis Bio, the company maintains comprehensive resources available through its official channels. The latest news and updates relating to ANVS are available in the company's newsroom at https://ibn.fm/ANVS. This presentation at a major investment conference underscores the company's active role in the biotechnology sector and its ongoing efforts to advance treatments for debilitating neurological conditions.